BRAF and melanoma: In our proof-of-principle efficacy study, we demonstrated successful administration of an orally available FDA-approved BRAFV600E inhibitor, Vemurafenib, to adult zebrafish harboring BRAF-mutant melanoma over the 2-week treatment course.